Back

Detection of Aggressive Mesenchymal Glioblastoma by Mannose-Weighted CEST MRI

Ghaemi, B.; Lopez-Bertoni, H.; Kuddannaya, S.; Sall, S.; Laterra, J.; Liu, G.; Bulte, J.

2025-04-17 cancer biology
10.1101/2025.04.15.648948 bioRxiv
Show abstract

Glioblastoma (GBM) contain mesenchymal cancer stem cells that drive tumor aggressiveness and recurrence and exhibit aberrant glycosylation during proneural-to-mesenchymal transition. A comprehensive analysis of human GBM transcriptomic datasets revealed an upregulation of 13 genes involved in mannosylation. Histopathological staining of a tissue array representing 35 GBM cases revealed elevated mannose, correlating with increased expression of the mesenchymal marker CD44. Mannose-weighted chemical exchange saturation transfer magnetic resonance imaging (MANw CEST MRI) detected elevated mannose levels in aggressive mesenchymal GBM neurospheres in vitro and in vivo, but not in less aggressive non-mesenchymal phenotype. To establish causation, inhibiting the expression of the mannose binding lectins LMAN1/2 that regulate intracellular processing of mannosylated proteins decreased the glioma cell MANw CEST MRI signal. Our findings indicate that MANw CEST MRI can visualize high mannose levels in mesenchymal GBM cells, which may serve as a surrogate imaging biomarker for predicting and assessing tumor aggressiveness and recurrence.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.